;PMID: 7928631
;source_file_1233.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:44..132] = [t:44..132]
;2)section:[e:136..199] = [t:136..199]
;3)section:[e:203..263] = [t:203..263]
;4)sentence:[e:267..549] = [t:267..549]
;5)sentence:[e:550..749] = [t:550..749]
;6)sentence:[e:750..889] = [t:750..889]
;7)sentence:[e:890..1001] = [t:890..1001]
;8)sentence:[e:1002..1061] = [t:1002..1061]
;9)sentence:[e:1062..1179] = [t:1062..1179]
;10)sentence:[e:1180..1276] = [t:1180..1276]
;11)sentence:[e:1277..1474] = [t:1277..1474]
;12)section:[e:1478..1522] = [t:1478..1522]

;section 0 Span:0..39
;Jpn J Cancer Res  1994 Aug;85(8):847-52
(SEC
  (FRAG (NNP:[0..3] Jpn) (NNP:[4..5] J) (NNP:[6..12] Cancer) (NNP:[13..16] Res)
        (CD:[18..22] 1994) (CC:[23..30] Aug;85-LRB-) (CD:[30..31] 8)
        (-RRB-:[31..32] -RRB-) (CD:[32..36] :847) (::[36..37] -)
        (CD:[37..39] 52)))

;sentence 1 Span:44..132
;State of adenomatous polyposis coli gene and ras oncogenes in Japanese
;prostate  cancer.
;[53..79]:gene-rna:"adenomatous polyposis coli"
;[89..92]:gene-rna:"ras"
;[115..131]:malignancy:"prostate  cancer"
(SENT
  (NP-HLN
    (NP (NN:[44..49] State))
    (PP (IN:[50..52] of)
      (NP
        (NP
           (JJ:[53..64] adenomatous) (NN:[65..74] polyposis) (NN:[75..79] coli)
          (NN:[80..84] gene))
        (CC:[85..88] and)
        (NP (NN:[89..92] ras) (NNS:[93..102] oncogenes))))
    (PP (IN:[103..105] in)
      (NP (JJ:[106..114] Japanese)
         (NN:[115..123] prostate) (NN:[125..131] cancer)))
    (.:[131..132] .)))

;section 2 Span:136..199
;Suzuki H, Aida S, Akimoto S, Igarashi T, Yatani R, Shimazaki J.
(SEC
  (FRAG (NNP:[136..142] Suzuki) (NNP:[143..144] H) (,:[144..145] ,)
        (NNP:[146..150] Aida) (NNP:[151..153] S,) (NNP:[154..161] Akimoto)
        (NNP:[162..164] S,) (NNP:[165..173] Igarashi) (NNP:[174..175] T)
        (,:[175..176] ,) (NNP:[177..183] Yatani) (NNP:[184..186] R,)
        (NNP:[187..196] Shimazaki) (NNP:[197..199] J.)))

;section 3 Span:203..263
;Department of Urology, School of Medicine, Chiba University.
(SEC
  (FRAG (NNP:[203..213] Department) (IN:[214..216] of) (NNP:[217..224] Urology)
        (,:[224..225] ,) (NNP:[226..232] School) (IN:[233..235] of)
        (NNP:[236..244] Medicine) (,:[244..245] ,) (NNP:[246..251] Chiba)
        (NNP:[252..262] University) (.:[262..263] .)))

;sentence 4 Span:267..549
;Genetic alterations of ras oncogenes (K-, H- and N-ras) and adenomatous 
;polyposis coli (APC) gene in tissues of prostate cancer from Japanese
;patients  were examined using PCR-SSCP (polymerase chain reaction-single
;strand  conformation polymorphism) analysis and direct sequencing.
;[290..293]:gene-rna:"ras"
;[305..307]...[309..311]...[316..318]...[318..321]:gene-rna:"K-"..."H-"..."N-"
;..."ras"
;[327..354]:gene-rna:"adenomatous  polyposis coli"
;[356..359]:gene-rna:"APC"
;[380..395]:malignancy:"prostate cancer"
;[450..460]:gene-protein:"polymerase"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[267..274] Genetic) (NNS:[275..286] alterations))
      (PP (IN:[287..289] of)
        (NP
          (NP (NN:[290..293] ras) (NNS:[294..303] oncogenes)
            (PRN (-LRB-:[304..305] -LRB-)
              (NP
                (NP (NN:[305..306] K) (HYPH:[306..307] -)
                  (NML-2 (-NONE-:[307..307] *P*)))
                (,:[307..308] ,)
                (NP (NN:[309..310] H) (HYPH:[310..311] -)
                  (NML-2 (-NONE-:[311..311] *P*)))
                (CC:[312..315] and)
                (NP (NN:[316..317] N) (HYPH:[317..318] -)
                  (NML-2 (NN:[318..321] ras))))
              (-RRB-:[321..322] -RRB-)))
          (CC:[323..326] and)
          (NP
            (NML
              (NML (JJ:[327..338] adenomatous) (NN:[340..349] polyposis)
                   (NN:[350..354] coli))
              (NML (-LRB-:[355..356] -LRB-) (NN:[356..359] APC)
                   (-RRB-:[359..360] -RRB-)))
            (NN:[361..365] gene))))
      (PP-LOC (IN:[366..368] in)
        (NP
          (NP (NNS:[369..376] tissues))
          (PP (IN:[377..379] of)
            (NP
              (NP (NN:[380..388] prostate) (NN:[389..395] cancer))
              (PP (IN:[396..400] from)
                (NP (JJ:[401..409] Japanese) (NNS:[410..418] patients))))))))
    (VP (VBD:[420..424] were)
      (VP (VBN:[425..433] examined)
        (NP-1 (-NONE-:[433..433] *))
        (S-MNR
          (NP-SBJ (-NONE-:[433..433] *))
          (VP (VBG:[434..439] using)
            (NP
              (NP
                (NML
                  (NML (NN:[440..443] PCR) (HYPH:[443..444] -)
                       (NN:[444..448] SSCP))
                  (NML (-LRB-:[449..450] -LRB-)
                    (NML (NN:[450..460] polymerase) (NN:[461..466] chain)
                         (NN:[467..475] reaction))
                    (HYPH:[475..476] -)
                    (NML
                      (NML (JJ:[476..482] single) (NN:[483..489] strand))
                      (NN:[491..503] conformation) (NN:[504..516] polymorphism))
                    (-RRB-:[516..517] -RRB-)))
                (NN:[518..526] analysis))
              (CC:[527..530] and)
              (NP (JJ:[531..537] direct) (NN:[538..548] sequencing)))))))
    (.:[548..549] .)))

;sentence 5 Span:550..749
;Tissues from 8 cases  of untreated stage B prostate cancer surgically removed
;and from 10 cases of  endocrine therapy-resistant metastatic disease obtained
;at autopsy were used in  the present study.
;[585..608]:malignancy:"stage B prostate cancer"
;[678..696]:malignancy:"metastatic disease"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[550..557] Tissues))
      (PP
        (PP (IN:[558..562] from)
          (NP
            (NP (CD:[563..564] 8) (NNS:[565..570] cases))
            (PP (IN:[572..574] of)
              (NP
                (NP (JJ:[575..584] untreated)
                  
                  (NML (NN:[585..590] stage) (NN:[591..592] B))
                  (NN:[593..601] prostate) (NN:[602..608] cancer))
                (VP
                  (ADVP-MNR (RB:[609..619] surgically))
                  (VBN:[620..627] removed)
                  (NP (-NONE-:[627..627] *)))))))
        (CC:[628..631] and)
        (PP (IN:[632..636] from)
          (NP
            (NP
              (NP (CD:[637..639] 10) (NNS:[640..645] cases))
              (PP (IN:[646..648] of)
                (NP
                  (ADJP
                    (NML (JJ:[650..659] endocrine) (NN:[660..667] therapy))
                    (HYPH:[667..668] -) (JJ:[668..677] resistant))
                   (JJ:[678..688] metastatic) (NN:[689..696] disease))))
            (VP (VBN:[697..705] obtained)
              (NP (-NONE-:[705..705] *))
              (PP (IN:[706..708] at)
                (NP (NN:[709..716] autopsy))))))))
    (VP (VBD:[717..721] were)
      (VP (VBN:[722..726] used)
        (NP-1 (-NONE-:[726..726] *))
        (PP (IN:[727..729] in)
          (NP (DT:[731..734] the) (JJ:[735..742] present) (NN:[743..748] study)))))
    (.:[748..749] .)))

;sentence 6 Span:750..889
;In four out of 18 cases (22%), ras point mutations were  found, two in either
;codon 12 or 61 of K-ras and two in either 13 or 61 of  H-ras.
;[781..784]:gene-rna:"ras"
;[785..800]:variation-type:"point mutations"
;[828..833]...[834..836]...[840..842]...[870..872]...[876..878]:variation-loca
;tion:"codon"..."12"..."61"..."13"..."61"
;[846..851]:gene-rna:"K-ras"
;[883..888]:gene-rna:"H-ras"
(SENT
  (S
    (PP (IN:[750..752] In)
      (NP
        (NP (CD:[753..757] four))
        (PP (IN:[758..761] out)
          (PP (IN:[762..764] of)
            (NP (CD:[765..767] 18) (NNS:[768..773] cases)
              (PRN (-LRB-:[774..775] -LRB-)
                (NP (CD:[775..777] 22) (NN:[777..778] %))
                (-RRB-:[778..779] -RRB-)))))))
    (,:[779..780] ,)
    (NP-SBJ-2 (NN:[781..784] ras)
       (NN:[785..790] point) (NNS:[791..800] mutations))
    (VP (VBD:[801..805] were)
      (VP (VBN:[807..812] found)
        (NP-2 (-NONE-:[812..812] *))
        (,:[812..813] ,)
        (FRAG
          (NP
            (NP
              (NP (CD:[814..817] two))
              (PP (IN:[818..820] in)
                (NP
                  (NP (CC:[821..827] either)
                    (NP
                      (NML-1 (NN:[828..833] codon))
                      (CD:[834..836] 12))
                    (CC:[837..839] or)
                    (NP
                      (NML-1 (-NONE-:[839..839] *P*))
                      (CD:[840..842] 61)))
                  (PP (IN:[843..845] of)
                    (NP (NN:[846..851] K-ras))))))
            (CC:[852..855] and)
            (NP
              (NP (CD:[856..859] two))
              (PP (IN:[860..862] in)
                (NP
                  (NP (CC:[863..869] either) (CD:[870..872] 13)
                      (CC:[873..875] or) (CD:[876..878] 61))
                  (PP (IN:[879..881] of)
                    (NP (NN:[883..888] H-ras))))))))))
    (.:[888..889] .)))

;sentence 7 Span:890..1001
;These point mutations were detected in one of the stage B cases (13%) and  in
;three of the autopsy cases (30%).
;[896..911]:variation-type:"point mutations"
;[940..947]:malignancy:"stage B"
(SENT
  (S
    (NP-SBJ-1 (DT:[890..895] These)
       (NN:[896..901] point) (NNS:[902..911] mutations))
    (VP (VBD:[912..916] were)
      (VP (VBN:[917..925] detected)
        (NP-1 (-NONE-:[925..925] *))
        (PP
          (PP (IN:[926..928] in)
            (NP
              (NP (CD:[929..932] one))
              (PP (IN:[933..935] of)
                (NP (DT:[936..939] the)
                  (NML (NN:[940..945] stage) (NN:[946..947] B))
                  (NNS:[948..953] cases)))
              (PRN (-LRB-:[954..955] -LRB-)
                (NP (CD:[955..957] 13) (NN:[957..958] %))
                (-RRB-:[958..959] -RRB-))))
          (CC:[960..963] and)
          (PP (IN:[965..967] in)
            (NP
              (NP (CD:[968..973] three))
              (PP (IN:[974..976] of)
                (NP (DT:[977..980] the) (NN:[981..988] autopsy)
                    (NNS:[989..994] cases)))
              (PRN (-LRB-:[995..996] -LRB-)
                (NP (CD:[996..998] 30) (NN:[998..999] %))
                (-RRB-:[999..1000] -RRB-)))))))
    (.:[1000..1001] .)))

;sentence 8 Span:1002..1061
;All these cases were poorly differentiated  adenocarcinoma.
;[1023..1060]:malignancy:"poorly differentiated  adenocarcinoma"
(SENT
  (S
    (NP-SBJ (PDT:[1002..1005] All) (DT:[1006..1011] these)
            (NNS:[1012..1017] cases))
    (VP (VBD:[1018..1022] were)
      (ADJP-PRD
        (ADJP (RB:[1023..1029] poorly) (VBN:[1030..1044] differentiated))
        (NN:[1046..1060] adenocarcinoma)))
    (.:[1060..1061] .)))

;sentence 9 Span:1062..1179
;In autopsy cases showing ras mutation in cancerous prostate, the  same
;alteration was observed in metastatic tissues.
;[1087..1090]:gene-rna:"ras"
;[1091..1099]:variation-event:"mutation"
;[1103..1121]:malignancy:"cancerous prostate"
;[1133..1143]:variation-event:"alteration"
;[1160..1178]:malignancy:"metastatic tissues"
(SENT
  (S
    (PP (IN:[1062..1064] In)
      (NP
        (NP (NN:[1065..1072] autopsy) (NNS:[1073..1078] cases))
        (VP (VBG:[1079..1086] showing)
          (NP (NN:[1087..1090] ras) (NN:[1091..1099] mutation))
          (PP (IN:[1100..1102] in)
            (NP (JJ:[1103..1112] cancerous) (NN:[1113..1121] prostate))))))
    (,:[1121..1122] ,)
    (NP-SBJ-1 (DT:[1123..1126] the) (JJ:[1128..1132] same)
              (NN:[1133..1143] alteration))
    (VP (VBD:[1144..1147] was)
      (VP (VBN:[1148..1156] observed)
        (NP-1 (-NONE-:[1156..1156] *))
        (PP (IN:[1157..1159] in)
          (NP (JJ:[1160..1170] metastatic) (NNS:[1171..1178] tissues)))))
    (.:[1178..1179] .)))

;sentence 10 Span:1180..1276
;No APC gene mutation was  detected in any sample, although polymorphism was
;found in some cases.
;[1183..1186]:gene-rna:"APC"
(SENT
  (S
    (NP-SBJ-2 (DT:[1180..1182] No) (NN:[1183..1186] APC) (NN:[1187..1191] gene)
              (NN:[1192..1200] mutation))
    (VP (VBD:[1201..1204] was)
      (VP (VBN:[1206..1214] detected)
        (NP-2 (-NONE-:[1214..1214] *))
        (PP (IN:[1215..1217] in)
          (NP (DT:[1218..1221] any) (NN:[1222..1228] sample)))
        (,:[1228..1229] ,)
        (SBAR-ADV (IN:[1230..1238] although)
          (S
            (NP-SBJ-1 (NN:[1239..1251] polymorphism))
            (VP (VBD:[1252..1255] was)
              (VP (VBN:[1256..1261] found)
                (NP-1 (-NONE-:[1261..1261] *))
                (PP (IN:[1262..1264] in)
                  (NP (DT:[1265..1269] some) (NNS:[1270..1275] cases)))))))))
    (.:[1275..1276] .)))

;sentence 11 Span:1277..1474
;These  results indicate that ras oncogene mutations are related to the
;progression of  prostate cancer, whereas APC gene alteration is not involved
;in tumorigenesis  and development of this cancer.
;[1306..1309]:gene-rna:"ras"
;[1364..1379]:malignancy:"prostate cancer"
;[1389..1392]:gene-rna:"APC"
;[1467..1473]:malignancy:"cancer"
(SENT
  (S
    (NP-SBJ (DT:[1277..1282] These) (NNS:[1284..1291] results))
    (VP (VBP:[1292..1300] indicate)
      (SBAR (IN:[1301..1305] that)
        (S
          (NP-SBJ-2 (NN:[1306..1309] ras) (NN:[1310..1318] oncogene)
                    (NNS:[1319..1328] mutations))
          (VP (VBP:[1329..1332] are)
            (VP (JJ:[1333..1340] related)
              (NP-2 (-NONE-:[1340..1340] *))
              (PP-CLR (TO:[1341..1343] to)
                (NP
                  (NP (DT:[1344..1347] the) (NN:[1348..1359] progression))
                  (PP (IN:[1360..1362] of)
                    (NP (NN:[1364..1372] prostate) (NN:[1373..1379] cancer)))))
              (,:[1379..1380] ,)
              (SBAR-ADV (IN:[1381..1388] whereas)
                (S
                  (NP-SBJ-1 (NN:[1389..1392] APC) (NN:[1393..1397] gene)
                            (NN:[1398..1408] alteration))
                  (VP (VBZ:[1409..1411] is) (RB:[1412..1415] not)
                    (VP (VBN:[1416..1424] involved)
                      (NP-1 (-NONE-:[1424..1424] *))
                      (PP (IN:[1425..1427] in)
                        (NP
                          (NP (NN:[1428..1441] tumorigenesis)
                              (CC:[1443..1446] and)
                              (NN:[1447..1458] development))
                          (PP (IN:[1459..1461] of)
                            (NP (DT:[1462..1466] this) (NN:[1467..1473] cancer))))))))))))))
    (.:[1473..1474] .)))

;section 12 Span:1478..1522
;PMID: 7928631 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1478..1482] PMID) (::[1482..1483] :) (CD:[1484..1491] 7928631)
        (NN:[1492..1493] -LSB-) (NNP:[1493..1499] PubMed) (::[1500..1501] -)
        (NN:[1502..1509] indexed) (IN:[1510..1513] for)
        (NNP:[1514..1522] MEDLINE-RSB-)))
